Long-Term Safety and Effectiveness of the Xanthine Oxidoreductase Inhibitor, Topiroxostat in Japanese Hyperuricemic Patients with or Without Gout: A 54-week Open-label, Multicenter, Post-marketing Observational Study

BACKGROUND AND OBJECTIVES: Topiroxostat, a selective xanthine oxidoreductase inhibitor, is used for the management of hyperuricemic patients with or without gout in Japan. Accumulating evidence has demonstrated the efficacy of topiroxostat for the treatment of hyperuricemia with or without gout. How...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishikawa, Tomohiko, Maeda, Tatsushi, Hashimoto, Teruo, Nakagawa, Tetsuya, Ichikawa, Kazuhito, Sato, Yasushi, Kanno, Yoshihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452866/
https://www.ncbi.nlm.nih.gov/pubmed/32621143
http://dx.doi.org/10.1007/s40261-020-00941-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452866/
https://www.ncbi.nlm.nih.gov/pubmed/32621143
http://dx.doi.org/10.1007/s40261-020-00941-3

Ejemplares similares